Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Cash & Equivalents (2021 - 2025)

LifeStance Health (LFST) has disclosed Cash & Equivalents for 5 consecutive years, with $248.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 105.68% to $248.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $248.6 million, a 105.68% increase, with the full-year FY2025 number at $248.6 million, up 105.68% from a year prior.
  • Cash & Equivalents was $248.6 million for Q4 2025 at LifeStance Health, up from $141.8 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $276.2 million in Q2 2021 to a low of $4.4 million in Q4 2022.
  • A 5-year average of $118.9 million and a median of $99.7 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 97.01% in 2022, then skyrocketed 1680.93% in 2023.
  • LifeStance Health's Cash & Equivalents stood at $148.0 million in 2021, then crashed by 97.01% to $4.4 million in 2022, then surged by 1680.93% to $78.8 million in 2023, then soared by 53.36% to $120.9 million in 2024, then surged by 105.68% to $248.6 million in 2025.
  • Per Business Quant, the three most recent readings for LFST's Cash & Equivalents are $248.6 million (Q4 2025), $141.8 million (Q3 2025), and $188.9 million (Q2 2025).